Rubedo Life Sciences focuses on developing medicines that target the specific cells responsible for aging, known as pathologic cells.
Rubedo Life Sciences has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
Rubedo Life Sciences's investors include Alumni Ventures, Khosla Ventures, Ahren Innovation Capital, Refactor, Modi Ventures.
Rubedo Life Sciences is headquartered in Sunnyvale, United States.
Rubedo Life Sciences focuses on developing medicines that target the specific cells responsible for aging, known as pathologic cells.
Rubedo Life Sciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rubedo Life Sciences — Funding & Investors." VCBacked, April 22, 2024, https://www.vcbacked.co/company/rubedo-life-sciences. Accessed October 29, 2026.
VCBacked. (2024). Rubedo Life Sciences — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/rubedo-life-sciences
{{cite web |title=Rubedo Life Sciences — Funding & Investors |url=https://www.vcbacked.co/company/rubedo-life-sciences |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated